Free Trial
NASDAQ:VIRX

Viracta Therapeutics (VIRX) Stock Price, News & Analysis

Viracta Therapeutics logo
$0.01 +0.00 (+26.73%)
As of 10:51 AM Eastern

About Viracta Therapeutics Stock (NASDAQ:VIRX)

Key Stats

Today's Range
$0.0091
$0.0128
50-Day Range
$0.01
$0.02
52-Week Range
$0.01
$0.58
Volume
2.41 million shs
Average Volume
595,534 shs
Market Capitalization
$508.72 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.75
Consensus Rating
Hold

Company Overview

Viracta Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

VIRX MarketRank™: 

Viracta Therapeutics scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Viracta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Viracta Therapeutics has received no research coverage in the past 90 days.

  • Read more about Viracta Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Viracta Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Viracta Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Viracta Therapeutics has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Viracta Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.02% of the float of Viracta Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Viracta Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Viracta Therapeutics has recently decreased by 41.73%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Viracta Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Viracta Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.02% of the float of Viracta Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Viracta Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Viracta Therapeutics has recently decreased by 41.73%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 1 people have searched for VIRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Viracta Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.69% of the stock of Viracta Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 31.37% of the stock of Viracta Therapeutics is held by institutions.

  • Read more about Viracta Therapeutics' insider trading history.
Receive VIRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VIRX Stock News Headlines

Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
Viracta Therapeutics terminates employees, to wind down operations
Viracta Therapeutics Announces Wind Down of Operations
See More Headlines

VIRX Stock Analysis - Frequently Asked Questions

Viracta Therapeutics' stock was trading at $0.1609 at the beginning of 2025. Since then, VIRX stock has decreased by 92.0% and is now trading at $0.0128.

Viracta Therapeutics, Inc. (NASDAQ:VIRX) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.09.

Shares of VIRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Viracta Therapeutics investors own include Meta Platforms (META), Intel (INTC), Applied Genetic Technologies (AGTC), C3.ai (AI), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/10/2021
Today
7/15/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VIRX
CIK
1061027
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$3.00
Low Price Target
$0.25
Potential Upside/Downside
+17,226.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$51.06 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,899.61%
Return on Assets
-114.21%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.76
Quick Ratio
0.76

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.33 per share
Price / Book
0.03

Miscellaneous

Outstanding Shares
39,744,000
Free Float
35,495,000
Market Cap
$401.41 thousand
Optionable
Optionable
Beta
1.06
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:VIRX) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners